1. Home
  2. AVDL vs BTO Comparison

AVDL vs BTO Comparison

Compare AVDL & BTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • BTO
  • Stock Information
  • Founded
  • AVDL 2015
  • BTO 1994
  • Country
  • AVDL Ireland
  • BTO United States
  • Employees
  • AVDL N/A
  • BTO N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • BTO Investment Managers
  • Sector
  • AVDL Health Care
  • BTO Finance
  • Exchange
  • AVDL Nasdaq
  • BTO Nasdaq
  • Market Cap
  • AVDL 764.3M
  • BTO 703.7M
  • IPO Year
  • AVDL 1996
  • BTO N/A
  • Fundamental
  • Price
  • AVDL $7.91
  • BTO $33.74
  • Analyst Decision
  • AVDL Strong Buy
  • BTO
  • Analyst Count
  • AVDL 7
  • BTO 0
  • Target Price
  • AVDL $18.86
  • BTO N/A
  • AVG Volume (30 Days)
  • AVDL 1.5M
  • BTO 54.2K
  • Earning Date
  • AVDL 03-03-2025
  • BTO 01-01-0001
  • Dividend Yield
  • AVDL N/A
  • BTO 9.13%
  • EPS Growth
  • AVDL N/A
  • BTO N/A
  • EPS
  • AVDL N/A
  • BTO N/A
  • Revenue
  • AVDL $169,117,000.00
  • BTO N/A
  • Revenue This Year
  • AVDL $51.49
  • BTO N/A
  • Revenue Next Year
  • AVDL $32.18
  • BTO N/A
  • P/E Ratio
  • AVDL N/A
  • BTO N/A
  • Revenue Growth
  • AVDL 504.79
  • BTO N/A
  • 52 Week Low
  • AVDL $7.39
  • BTO $22.95
  • 52 Week High
  • AVDL $19.09
  • BTO $32.81
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 43.28
  • BTO 27.41
  • Support Level
  • AVDL $7.45
  • BTO $33.47
  • Resistance Level
  • AVDL $7.97
  • BTO $36.24
  • Average True Range (ATR)
  • AVDL 0.37
  • BTO 0.99
  • MACD
  • AVDL -0.01
  • BTO -0.31
  • Stochastic Oscillator
  • AVDL 33.82
  • BTO 16.77

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About BTO John Hancock Financial Opportunities Fund

John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The portfolio composition of the fund includes common stocks, corporate bonds, preferred securities, investment companies, and short-term investments.

Share on Social Networks: